admin

Posts by admin:

2Ap01

The global market for prophylactic HPV vaccines is likely to grow rapidly as more and more countries expand national vaccination programs to include HPV vaccinations not only for girls but also forboys. In addition, it is now estimated that 60-70% of oropharyngeal cancers are caused by HPV virus infections, opening up a discussion on HPV vaccinations for adults too.
...

READ MORE

2AP02

2A Pharma’s AAVLP-HER2/Neu peptide vaccine candidate has in laboratory tests been shown to induce antibodies specific to human HER2. In mouse models, regression of breast cancer tumors wasobserved after vaccination. In a proof-of-principle study carried out at the Medical University of Vienna, Austria, supported by Medigene AG, it was concluded that this vaccine strategy could help to...

READ MORE

2AP03

2A Pharma’s B-cell epitope vaccine candidate, AAVLP-IgE, has in laboratory tests with non-human primates been shown to be effective at inducing anti-IgE autoantibodies. This gives the potentialfor a vaccine with similar benefits to approved anti‐human immunoglobulin E (IgE) antibody treatments of, for example, asthma, nut allergy etc. Currently, the potential of a bivalent AAVLP-IgE...

READ MORE

2AP04

2A Pharma’s anti-amyloid-beta vaccine candidate, AAVLP-Amyloid-β, has in laboratory tests with transgenic mice over-expressing amyloid-beta mutant protein been shown to eliminate amyloid-betasoluble protein, a clear plaque from the cortex and significantly reduce plaque from the hippocampus.

...

READ MORE

2AP05

2A Pharma’s anti-autoimmune vaccine candidate has potential in a number of indications. The vaccine is currently being tested in a vitiligo model in collaboration with different partners.

READ MORE

2AP07

Head and neck cancers represent the sixth most common cancer worldwide, resulting in more than 350,000 deaths/year. Our AAVLP-HNC vaccine uses our mimotope selection technology and has thepotential to minimize side effects, improve efficacy, and markedly reduce treatment costs. This will address an unmet medical need and benefit cancer patients as well as reduce healthcare expenses. In...

READ MORE

Dosing completed

All volunteers have now received three doses of 2AP01 (AAVLP-HPV), our very broad spectrum HPV vaccine formulated without adjuvant. The vaccine is well tolerated and no serious adverse events (SAEs)have been observed to date.
...

READ MORE

Article in MedWatch

Article about 2A Pharma in the Danish pharma/biotech media MedWatch (behind paywall):

Danish: https://medwatch.dk/secure/Medicinal___Biotek/article11272123.ece
English: https://medwatch.dk/secure/Top_picks_in_english/article11274345.ece

READ MORE

2A PHARMA INITIATES PHASE 1 CLINICAL TRIAL OF HPV VACCINE CANDIDATE

Malmö, Sweden – 13 March 2019
2A Pharma, the Swedish/Danish vaccine company today announced that, approximately 27 months after the company was founded, its novel, broad coverage, HPV L2 vaccine candidate formulated without...

READ MORE